海思科控股股东王俊民妻子减持125万股，公司股价上月刚创历史新高

Core Viewpoint - The recent share reduction by a significant shareholder of Haishike (002653.SZ) indicates personal financial needs, while the company continues to pursue a private placement to raise funds for new drug development and working capital [2][4]. Group 1: Shareholder Actions - On September 14, Haishike announced that shareholder Shen Ping plans to reduce her holdings by 1.25 million shares, representing 0.11% of the total share capital, between September 1 and September 12, 2025 [1]. - Following this reduction, the combined shareholding of Shen Ping and her husband Wang Junmin decreased from 4.49 billion shares to 4.48 billion shares, with their total ownership percentage dropping from 40.11% to 40.00% [1][3]. - Shen Ping's previous reductions included over 6 million shares earlier this year, and she has plans to further reduce her holdings by up to 10.37 million shares in the coming months [3][4]. Group 2: Financial Performance - In the first half of the year, Haishike reported revenue of 2 billion yuan, an increase of 18.63% year-on-year, while net profit attributable to shareholders fell by 21.79% to 129 million yuan [5]. - The core product,环泊酚注射液, contributed significantly to sales, achieving approximately 800 million yuan in revenue, a 55% increase year-on-year [5]. - As of the mid-year report, Haishike had 17 innovative drug products in clinical stages, with total R&D expenses amounting to 342 million yuan [5]. Group 3: Fundraising Activities - Haishike is actively pursuing a private placement, with the Shenzhen Stock Exchange having accepted its application to issue up to 70 million shares, aiming to raise a maximum of 1.365 billion yuan [4]. - The funds raised are intended for new drug development (approximately 965 million yuan) and to supplement working capital (400 million yuan) [4].